Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy, irinotecan, and capecitabine before excision for locally advanced rectal cancer
ISRCTN59158409Phase 2Completed
- Sponsor
- Conwy and Denbighshire NHS Trust
- Start
- Sep 2003
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of capecitabine and irinotecan in rectal cancer, sponsored by Conwy and Denbighshire NHS Trust. Primary endpoints: Safety and recommended dose of combination of radiotherapy, capecitabine and irinotecan and Histological pathological complete response rate. Started Sep 2003; status: completed.
02
Drugs
capecitabineirinotecan
03
Conditions
rectal cancer
Beyond the preview
Go deeper on ISRCTN59158409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN59158409.